

CLAIMS

What is claimed is:

1. A method for treating Parkinson's disease using
5 an oral dosage formulation comprising an immediate release
layer of 10-25 mg of carbidopa and 50-200 mg of levodopa and
a sustained release layer of 25-75 mg of carbidopa and 100-
400 mg of levodopa whereby, following administration,
carbidopa and levodopa are available for rapid and sustained
10 therapeutic action.
2. A method as claimed in Claim 1 characterized by
a sustained release core depot of carbidopa-levodopa
overcoated by an immediate release layer of carbidopa-
levodopa.
3. A method as claimed in Claim 1 characterized by
15 a multilayer tablet comprising at least one layer of
sustained release carbidopa-levodopa adjacent to at least
one layer of immediate release carbidopa-levodopa.
4. A method of Claim 3 wherein the layers in the
20 tablet are separated by an excipient layer.
5. A pharmaceutical composition in oral dosage
form for treating Parkinson's disease comprising a
combination of an immediate release portion of a combination
of carbidopa and levodopa and a sustained release portion of
25 a combination of carbidopa and levodopa, the composition
effective in treating Parkinson's disease, and a
pharmaceutically acceptable vehicle, and whereby the
carbidopa and levodopa are available for immediate and
sustained therapeutic action upon administration.
6. The pharmaceutical composition of Claim 5
30 wherein the dosage form comprises a sustained release core
portion of carbidopa and levodopa overcoated by an immediate
release layer of carbidopa and levodopa.
7. The pharmaceutical composition of Claim 5
35 wherein the dosage form comprises a multilayer tablet
comprising at least one layer of sustained release
carbidopa-levodopa adjacent to at least one layer of
immediate release carbidopa-levodopa.

8. The pharmaceutical composition of Claim 5 wherein the immediate release portion comprises about 10-25 mg of carbidopa and 50-200 mg of levodopa and a sustained release portion of about 25-75 mg of carbidopa and 100-400 mg of levodopa.

9. The pharmaceutical composition of Claim 8 wherein the dosage form comprises a sustained release core portion of carbidopa-levodopa overcoated by an immediate release layer of carbidopa-levodopa.

10. The pharmaceutical layer of Claim 8 wherein the dosage form comprises a multilayer tablet of at least one layer of sustained release carbidopa-levodopa adjacent to at least one layer of immediate release carbidopa-levodopa.

add
all

add
xl

add
E'